Desai Madhav, Nutalapati Venkat, Srinivasan Sachin, Fathallah Jihan, Dasari Chandra, Chandrasekhar Viveksandeep Thoguluva, Mohammad Bilal, Kohli Divyanshoo, Vaezi Michael, Katz Philip O, Sharma Prateek
Department of Gastroenterology, Kansas City VA Medical Center, Kansas City, Missouri, USA.
Department of Gastroenterology and Hepatology, University of Kansas Medical Center, Kansas City, Kansas, USA.
Dis Esophagus. 2020 Oct 12;33(10). doi: 10.1093/dote/doaa041.
Published studies have reported variable results on the association between duration of proton pump inhibitor (PPI) use and the risk of dementia. An extensive literature search was performed in PubMed, Embase, Google Scholar, and Cochrane for studies examining the risk of cognitive decline and dementia among PPI users versus non-PPI users in prospective studies. Retrospective database linkage studies, case reports, case series, editorials, uncontrolled cohort studies, cross-sectional studies, and review articles were excluded. Primary outcome was pooled hazard rate (HR) of any dementia among PPI users compared with non-PPI users. Secondary outcomes were pooled HR of Alzheimer's dementia (AD) and risk with long-term PPI follow-up (more than 5 years) studies. Meta-analysis outcomes, heterogeneity (I2), and meta-regression (for the effect of covariates) were derived by statistical software R and Open meta-analyst. A total of six studies (one RCT and five prospective) with 308249 subjects, average age of 75.8 ± 5.2 years, and follow-up of 5 (range 1.5-11) years were included in the analysis. Pooled HR of any dementia was 1.16 (n = 6, 95% confidence interval (CI) = 0.86-1.47). Results remained unchanged when only studies with long-term PPI use (more than 5 years) were analyzed (n = 4, pooled HR 1.10, 95% CI 0.66-1.53). Finally, the pooled HR for AD was 1.06 (n = 3, 95% CI 0.70-1.41). There was substantial heterogeneity among inclusion studies (I2 = 93%). Meta-regression did not demonstrate a significant role of age at study start (P = 0.1) or duration of PPI use (P = 0.62) to incident dementia. The results of this systematic review and meta-analysis do not show a significant relationship between PPI use and dementia in prospective studies with at least a 5-year follow-up.
已发表的研究报告了质子泵抑制剂(PPI)使用时长与痴呆风险之间的关联结果不一。我们在PubMed、Embase、谷歌学术和考克兰图书馆进行了广泛的文献检索,以查找在前瞻性研究中比较PPI使用者与非PPI使用者认知功能下降和痴呆风险的研究。排除回顾性数据库关联研究、病例报告、病例系列、社论、非对照队列研究、横断面研究和综述文章。主要结局是PPI使用者与非PPI使用者相比患任何痴呆的合并风险比(HR)。次要结局是阿尔茨海默病(AD)的合并HR以及长期PPI随访(超过5年)研究的风险。通过统计软件R和Open meta-analyst得出荟萃分析结果、异质性(I²)和荟萃回归(用于协变量的效应)。分析纳入了六项研究(一项随机对照试验和五项前瞻性研究),共308249名受试者,平均年龄75.8±5.2岁,随访时间为5年(范围1.5 - 11年)。任何痴呆的合并HR为1.16(n = 6,95%置信区间(CI)= 0.86 - 1.47)。仅分析长期使用PPI(超过5年)的研究时结果不变(n = 4,合并HR 1.10,95% CI 0.66 - 1.53)。最后,AD的合并HR为1.06(n = 3,95% CI 0.70 - 1.41)。纳入研究之间存在显著异质性(I² = 93%)。荟萃回归未显示研究开始时的年龄(P = 0.1)或PPI使用时长(P = 0.62)对新发痴呆有显著作用。这项系统评价和荟萃分析的结果表明,在至少随访5年的前瞻性研究中,PPI使用与痴呆之间无显著关系。